Akebia Therapeutics vs Aurinia Pharmaceuticals
AKBA and AUPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AKBA and AUPH compare
Aurinia Pharmaceuticals is the larger company, worth 16 times as much as Akebia Therapeutics ($2.1B against $131M).
Aurinia Pharmaceuticals grew revenue faster over the last twelve months (21.0% versus −12.4% for Akebia Therapeutics).
Aurinia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 97.7% compared with −22.6% at Akebia Therapeutics.
Aurinia Pharmaceuticals scores higher on the StockData Score (13 against 4 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AKBA | AUPH |
|---|---|---|
| Size and price | ||
| Market cap | $131M | $2.1B |
| Share price | $0.474 | $15.73 |
| Change, 1 year | −74.4% | 1.2% |
| Change, 5 years | −82.9% | −44.7% |
| Beta (5Y) | 1.10 | 1.06 |
| Employees | 194 | 128 |
| StockData Score | ||
| Total score | 4 | 13 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 3 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 6.9× |
| P/S | 0.7× (better) | 6.6× |
| P/B | 6.5× | 3.2× (better) |
| EV/EBITDA | – | 11.7× |
| P/FCF | 9.5× | – |
| FCF yield | 10.5% | – |
| Fair value | – | $41.31 |
| Margin of safety | – | 61.9% |
| Growth | ||
| Revenue growth (TTM) | −12.4% | 21.0% (better) |
| Revenue growth, 5Y average | −4.3% | 41.4% (better) |
| Net income growth (TTM) | – | 304% |
| EPS growth (TTM) | – | 309% |
| Profitability | ||
| Gross margin | 78.9% | 90.6% (better) |
| Operating margin | −15.7% | 48.6% (better) |
| Net margin | −22.6% | 97.7% (better) |
| FCF margin | 7.0% | – |
| Return on equity | −144% | 61.4% (better) |
| Return on invested capital | – | 34.6% |
| Financial health | ||
| Debt / equity | 2.47 | – |
| Interest coverage | – | 40.4× |
| Current ratio | 1.36 | 6.12 (better) |
| Altman Z-score | −6.30 | 8.32 (better) |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.6% |
| Shareholder yield | 0.00% | 3.6% (better) |
| Ownership | ||
| Held by institutions | 39.7% | 58.3% |
| Held by insiders | 2.9% | 17.3% |
| Insider net buying, 12 months | −$876K | $24.6M (better) |
| Short interest, % of float | 10.1% | 6.4% |
Go deeper
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
- AUPH stock overview
- AUPH income statement
- AUPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.